Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women

• Main Authors: Cressey T.R., Van Dyke R., Jourdain G., Puthanakit T., Roongpisuthipong A., Achalapong J., Yuthavisuthi P., Prommas S., Chotivanich N., Maupin R., Smith E., Shapiro D.E., Mirochnick M.
• Format: Article
• Language: English
• Published: 2014
• Online Access: http://www.scopus.com/inward/record.url?eid=2-s2.0-66149098490&partnerID=40&md5=5a45497e177f994e7ade742a58781835; http://cmuir.cmu.ac.th/handle/6653943832/778
• Institution: Chiang Mai University

Lopinavir (LPV) exposure is reduced during the third trimester of pregnancy. We report the pharmacokinetics of standard LPV-ritonavir dosing (400/100 mg twice daily) in the immediate and early postpartum period when initiated during labor. In 16 human immunodeficiency virus-infected Thai women, the median (range) LPV area under the concentration-time curve and maximum and minimum concentrations in plasma were 99.7 (66.1 to 180.5) μg·h/ml, 11.2 (8.0 to 17.5) μg/ml, and 4.6 (1.7 to 12.5) μg/ml, respectively, at 41 (12 to 74) h after delivery. All of the women attained adequate LPV levels through 30 days postpartum. No serious adverse events were reported. Copyright © 2009, American Society for Microbiology. All Rights Reserved.